Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
65.81 USD | +1.90% | +1.46% | -18.87% |
May. 07 | Ligand Pharmaceuticals Investing in Agenus to Fund Development of Oncology Drug Candidates | MT |
May. 02 | UBS Adjusts Price Target on Gilead Sciences to $70 From $75, Maintains Neutral Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.87% | 80.53B | |
+31.10% | 695B | |
+26.51% | 568B | |
-4.69% | 361B | |
+19.64% | 330B | |
+3.58% | 283B | |
+16.70% | 239B | |
+8.78% | 204B | |
-7.93% | 198B | |
+9.03% | 168B |
- Stock Market
- Equities
- GILD Stock
- News Gilead Sciences, Inc.
- Gilead Sciences : Morgan Stanley Adjusts Price Target on Gilead Sciences to $83 From $81, Maintains Overweight Rating